Inicio>>Signaling Pathways>> Membrane Transporter/Ion Channel>> TRP Channel>>TCS 5861528

TCS 5861528 (Synonyms: TCS 5861528)

Catalog No.GC11185

TCS 5861528 (TCS 5861528) es un potente antagonista del canal TRPA1 que antagoniza de manera similar las respuestas de TRPA1 provocadas por isotiocianato de alilo y 4-HNE, con valores IC50 de 14,3 μM y 18,7 μM, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

TCS 5861528 Chemical Structure

Cas No.: 332117-28-9

Tamaño Precio Disponibilidad Cantidad
10mg
108,00 $
Ship Within 7 Days
50mg
451,00 $
Ship Within 7 Days
500mg
2.678,00 $
Ship Within 7 Days
1g
4.120,00 $
Ship Within 7 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Chembridge-5861528 is a TRPA1 channel blocker that antagonizes AITC- and 4-HNE-evoked calcium influx (IC50 values are 14.3 and 18.7μM respectively).

References:
[1]. Wei H, et al. Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology. 2009 Jul;111(1):147-54.
[2]. Wei H, et al. Roles of cutaneous versus spinal TRPA1 channels in mechanical hypersensitivity in the diabetic or mustard oil-treated non-diabetic rat. Neuropharmacology. 2010 Mar;58(3):578-84.
[3]. Wei H, et al. Spinal TRPA1 ion channels contribute to cutaneous neurogenic inflammation in the rat. Neurosci Lett. 2010 Aug 2;479(3):253-6.

Reseñas

Review for TCS 5861528

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TCS 5861528

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.